Liu Jiang, Liu Jianhua, Yu Jianhe, Ren Qun, Cai Yin, Chen Dadong, Song Chuanjun
Department of Oncology, Xinghua People's Hospital Affiliated to Yangzhou University, 419 Ying Wu Nan Road, Xinghua, 225700, Jiangsu, People's Republic of China.
J Transl Med. 2025 May 30;23(1):600. doi: 10.1186/s12967-025-06589-x.
The human epidermal growth factor receptor 2 (HER2) alterations are significant genetic alterations in non-small cell lung cancer (NSCLC), encompassing mutations, amplifications, and protein overexpression. Despite the substantial progress of anti-HER2 targeted therapies in breast and gastric cancers, numerous challenges persist in the treatment of NSCLC with HER2 alterations. Presently, the options for NSCLC with HER2 alterations remain limited, with inferior efficacy observed using small molecule anti-tumor targeted agents and conventional chemotherapy. Antibody drug conjugates (ADCs), an organic combination of monoclonal antibodies and cytotoxic drugs targeting specific tumor cells, have revolutionized the treatment landscape of NSCLC with HER2 alterations. Extensive exploration of ADCs has been conducted across NSCLC patients with HER2 alterations, achieving notable efficacy in some populations. This review aims to delve into the biological characteristics and current treatment landscape of NSCLC with HER2 alterations, emphasizing the transformative research advancements surrounding ADCs. By highlighting these developments, we aspire to provide essential insights to enhance clinical practice and improve management strategies for NSCLC patients with HER2 alterations.
人表皮生长因子受体2（HER2）改变是非小细胞肺癌（NSCLC）中显著的基因改变，包括突变、扩增和蛋白过表达。尽管抗HER2靶向治疗在乳腺癌和胃癌治疗中取得了重大进展，但在HER2改变的NSCLC治疗中仍存在诸多挑战。目前，HER2改变的NSCLC治疗选择仍然有限，使用小分子抗肿瘤靶向药物和传统化疗观察到的疗效较差。抗体药物偶联物（ADC），即单克隆抗体与靶向特定肿瘤细胞的细胞毒性药物的有机结合物，彻底改变了HER2改变的NSCLC治疗格局。已对HER2改变的NSCLC患者广泛探索了ADC，在一些人群中取得了显著疗效。本综述旨在深入探讨HER2改变的NSCLC的生物学特征和当前治疗格局，强调围绕ADC的变革性研究进展。通过突出这些进展，我们希望提供重要见解，以加强临床实践并改善HER2改变的NSCLC患者的管理策略。
